Extract from our Nordic M&A Newsletter

Read more about our Nordic M&A Newsletter service including the M&A Portal and Private Equity Portfolio Tracker.
Ultimovacs to apply for listing on Oslo Stock Exchange
May 21, 2019

The Norwegian-based pharmaceutical firm Ultimovacs has applied for listing on Oslo Stock Exchange. Ultimovacs is developing the world’s first universal cancer vaccine. The IPO pre-money values the firm at NOK 500m and Ultimovac expects to raise NOK 370m. In 2018, Ultimovac reported no turnover and EBIT of NOK 56.5m.

ⓘ This story was originally featured in our daily Nordic M&A Newsletter - we publish some of the newsletter content with delay through our M&A Newsletter Library. If you would like more insights on this deal or industry then send us an email at requests@nordicknowledgepartners.com